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Abstract
Objectives: Addiction and overdose related to prescription drugs continues to be a leading cause 
of morbidity and mortality in the US. We aimed to characterize the prescribing of opioids and 
benzodiazepines to patients who had previously presented with an opioid or benzodiazepine 
overdose.
Methods: This was a retrospective chart review of patients who were prescribed an opioid or 
benzodiazepine in a one-month time-period in 2015 (May) and had a previous presentation for 
opioid or benzodiazepine overdose at a large healthcare system.
Results: We identified 60,129 prescribing encounters for opioids and/or benzodiazepines, 543 of 
which involved a patient with a previous opioid or benzodiazepine overdose. There were 404 
Corresponding Author: Christopher Griggs, MD, Department of Emergency Medicine, Carolinas Medical Center, 1000 Blythe Blvd 
Charlotte, NC 28203, Christopher.Griggs@atriumhealth.org, Phone number: 704-355-7059, Fax number: 704-355-8708.
*PRIMUM Group (in alphabetical order): Michael Beuhler, MD2; Michael J. Bosse, MD1; Ryan Fogg1, BS; Michael Gibbs, MD3; 
Eric Haas, BS1; Steven Jarrett, PharMD4; Daniel Leas, MD1; Animita Saha, MD5; Sharon Schiro, PhD1; Bradley Watling, MD6
Meetings: Presented as a poster at American College of Emergency Physician in Las Vegas, NV October 2016 and at American Public 
Health Association in Denver, CO October 2016.
Competing Interests: The authors declare that they have no competing interests.
HHS Public Access
Author manuscript
J Addict Med. Author manuscript; available in PMC 2020 September 04.Author M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
unique patients in this cohort, with 97 having more than one visit including a prescription opioid 
and/or benzodiazepine. A majority of prescriptions (54.1%) were to patients with an overdose 
within the two years of the documented prescribing encounter. Prescribing in the outpatient 
clinical setting represented half (49.9%) of encounters, while emergency department prescribing 
was responsible for nearly a third (31.5%).
Conclusions: In conclusion, prescribing of opioids and benzodiazepines occurs across multiple 
locations in a large health care system to patients with a previous overdose. Risk factors such as 
previous overdose should be highlighted through clinical decision support tools in the medical 
record to help prescribers identify patients at higher risk and to mobilize resources for this patient 
population. Prescribers need further education on factors that place their patients at risk for opioid 
use disorder and on alternative therapies to opioids and benzodiazepines.
Introduction
Opioid use disorder continues to be a leading cause of morbidity and mortality in the US. 
Since 1999, the prescribing of opioids as well as the number of opioid-related deaths have 
both nearly quadrupled (Centers for Disease Control and Prevention 2016). Despite poor 
evidence that opioid therapy improves pain or function in chronic noncancer pain, opioids 
continue to be prescribed in large quantities to this patient population (Chou et al. 2015). 
There is good evidence that opioid therapy is effective in multiple acute pain conditions, but 
the introduction of opioids to patients with these conditions has been associated with the risk 
of progressing to long term dependency (Hoppe et al. 2015, Shah et al. 2017). Several 
patient specific factors have been associated with risk of progressing to opioid use disorder, 
including previous psychological disorder and substance use disorder (Dufour et al. 2014).
Previous opioid overdose is a particularly high-risk characteristic in patients receiving 
opioids for pain. Larochelle et al. showed that 91% of commercially insured adults with a 
history of nonfatal overdose while on chronic opioid therapy for noncancer pain received an 
opioid prescription within 299 days following an opioid overdose, suggesting that risky 
prescribing patterns are a potential driver for the ongoing epidemic (Larochelle et al. 2015). 
A similar study by Naeger et al. used claims data to examine prescribing practices following 
opioid-related admissions and demonstrated 22% of patients filled a prescription for an 
opioid pain reliever and 14% filled a prescription for a benzodiazepine within 30 days post-
discharge (Naeger et al. 2016). The use of insurance claims data in these studies limits the 
ability to further characterize the population and prescribing practices.
In addition to an increase in opioids over the past two decades, there has also been a 
substantial increase in the prescribing of benzodiazepines and in the prevalence of 
benzodiazepine use disorder. The number of prescriptions for benzodiazepines increased 
67% between 1996 and 2013, while the total amount of benzodiazepines filled has more 
than tripled (Bachhuber et al. 2016). Overdose deaths often involve both benzodiazepines 
and opioids. Opioids are involved in approximately 75% of benzodiazepine overdose deaths, 
while benzodiazepine are involved in 31% of opioid overdose deaths (Jones and McAninch 
2015). The increasing concurrent use of benzodiazepines and opioids is cited as a cause for 
increases in overdoses across the US (Warner et al. 2016, Sun et al. 2017).
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Those who misuse oral opioid medications often fail to perceive the risk of ongoing use 
despite data showing high risk of overdose and death (Frank et al. 2015). Furthermore, those 
with concurrent use of benzodiazepines and opioids fail to perceive the increased risk of 
overdose (Rowe et al. 2016). Neuroscience research suggests that chronic opioid exposure 
may increase impulsivity and risk taking and affect risk perception in those using opioids 
(Baldacchino et al. 2016). This highlights the imperative of prescribers to evaluate the risk of 
further opioid and benzodiazepine prescribing in those who have previously overdosed.
The purpose of this study is to determine the prevalence of history of overdose among the 
patients being prescribed controlled substances and provide a more detailed descriptive 
analysis of these encounters and patients across a large healthcare system. We aim to expand 
on previous research by examining the characteristics of the preceding overdose, of the 
patient, and of the subsequent controlled substance prescribing encounter through medial 
record abstraction.
Methods
This study was a retrospective chart review of patients at a large healthcare system with 
greater than 12 million patient encounters per year. An electronic tool embedded in our 
EMR (CERNER™) collects data whenever a prescription for a controlled substance is 
written. This occurs for all controlled substance prescriptions written, including at discharge 
from an inpatient admission, from the emergency department, from an urgent care, or from 
an outpatient visit. This tool has since been used to power an alert which displays to 
prescribers at the point of care when a patient meets one or more of identified risk criteria 
for substance use disorder of opioids or benzodiazepines. A full description of the 
development of this tool and the selection of risk factors has been previously described 
(Seymour et al. 2016). One risk factor recorded in this database is a documented opioid or 
benzodiazepine overdose within the patient’s electronic medical record (EMR) in our 
system, which includes data from 2007-present. Specifically, this database automatically 
pulls the diagnosis codes listed in Table 1. Our healthcare system includes more than 40 
hospitals and over 900 care locations. All providers use a common EMR, which houses 
more than 7 million patient records and captures information from 2007 to present date. We 
used one month of data from 2015 to identify patients who were prescribed a 
benzodiazepine or opioid (excluding buprenorphine) during that month and had a previous 
presentation for opioid or benzodiazepine overdose within the large healthcare system. 
Patients whose original overdose was determined to be a “treatment error” (overdose which 
occurred even though patient took the medication as prescribed) were later excluded from 
this analysis. Type of pain or diagnosis were not criteria for inclusion or exclusion. 
Prescribers were unaware of previous overdose or patient specific risk factors unless they 
searched through the EMR to find this information. There were no alerts provided to the 
prescribers during the time of this study.
All data abstraction was performed by trained research analysts supervised by the lead 
author and research team. A subset of charts (n=54) was abstracted by two physicians in 
addition to the abstractors early in the data collection process to determine reliability of 
information collected and to provide guidance as necessary. During this process, the authors 
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found agreement on type of overdose in 63% of patients. To improve reliability, additional 
guidance was given to the abstractors and the case report form was changed to capture 
objective criteria to determine cause of overdose (i.e. whether suicide was mentioned in the 
notes; whether a psychiatry consult was ordered; the conclusion of the psychiatry consult; 
and whether the diagnosis code indicated suicide attempt), rather than having the abstractor 
make a subjective conclusion. A preliminary data abstraction from the EMR was performed 
on these patients to determine the cause of the overdose as either 1) a suicide attempt, 2) 
unintentional (defined as self-induced without suicidal intent), 3) treatment error (taken as 
prescribed), or 4) unknown. The overdose was determined to be a “suicide attempt” if a 
diagnosis code indicated suicide, suicide was mentioned in the physician notes, and/or the 
patient received a psychiatry consult which determined suicidal intention. The unintentional 
category includes the intention to use the opioid or benzodiazepine for reasons other than 
prescribed without the intention of self-harm or an overdose that occurred while taking an 
opioid or benzodiazepine as prescribed but while using another substance such as alcohol. 
This categorization was based on medical documentation by the emergency provider, 
inpatient providers, and any psychiatric consultations provided during the visit. Treatment 
errors were defined as an overdose that occurred even though the patient took the medication 
as prescribed. For this paper, we chose to limit the patient population to those considered 
suicide attempts, unintentional, or unknown (n=404). We excluded those with treatment 
error (n = 9) since this category is felt to be lower risk for subsequent prescribing if correct 
dosing is chosen. For this subgroup of patients, we performed a more detailed data 
abstraction to determine cause of overdose, substances involved in overdose, medication 
prescribed at subsequent health system encounter, location of subsequent encounter, and 
other comorbidities. Comorbidities were included if the condition was listed anywhere in 
patient’s chart; they were not limited to diagnoses for the specific encounter or a specific 
time frame. Data were entered into REDCap electronic data capture tools hosted at 
Carolinas HealthCare System (Harris et al. 2009 Apr), and descriptive statistical analysis 
was performed with Statistical Analysis System (SAS® version 9.4, Copyright © 2012 SAS 
Institute Inc., Cary, NC, USA). This research study was conducted with approval of Atrium 
Health Institutional Review Board and did not require patient consent.
Results
Over the one-month period examined, our system had 770,431 patient encounters, of which 
60,129 included a prescription for an opioid and/or benzodiazepine (Figure 1). Of these 
prescribing encounters, 543 involved a patient with a previous opioid or benzodiazepine 
overdose coded in the EMR (0.9%). There were 404 unique patients in this cohort, with 97 
patients having more than one visit with a prescription during the one-month study period.
Most patients were between 35–64 years old (70.5%; mean age 46.9). Benzodiazepines 
without opioids accounted for 51.2% (N=207) of overdoses in this cohort, while opioids 
were involved alone in 74 cases or in combination with benzodiazepines in 114 cases (Table 
2). We did not determine whether the opioid or benzodiazepine contributing to the overdose 
was a prescribed medication, nonmedical or recreational use of the medication, or an illicit 
substance. The leading cause of overdose was determined to be unintentional at 51.0% of the 
examined overdoses and suicide attempts accounted for 40.3% of the overdose. Patients in 
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this cohort had a high burden of mental health comorbidities with 54.5% diagnosed with 
anxiety and 55.2% diagnosed with depression. Additionally, comorbid diagnoses included 
substance use disorder (29.2%), bipolar disorder (24.0%), and schizophrenia (4.2%).
Most patient encounters (54.1%) were for patients who had received an opioid or 
benzodiazepine prescription within two years of the documented overdose (Table 3). 
Opioids were prescribed more often than benzodiazepines (71.8% vs. 23.2%, respectively). 
At 27 of these encounters (5.0%), patients received prescriptions for both a benzodiazepine 
and an opioid. Hydrocodone and oxycodone containing opioids were the most frequently 
prescribed medications (56.0%).
Most of these prescriptions were written in outpatient clinical settings, including outpatient 
primary care, specialty care, outpatient procedures(49.9%). A large subset of these 
outpatient encounters included prescriptions written after medical phone call consultation 
accounted for a significant proportion of prescribing encounters (27.4%). Emergency 
department prescribing also accounted for a significant proportion of prescribing (31.5%). 
Primary care office visits accounted for 13.1% of prescribing. Behavioral health (5.2%) and 
cancer care (0.7%), accounted for a small proportion of the prescribing. Out of the 543 
prescribing encounters, we were able to identify diagnosis codes for 299 encounters in the 
billing data. There were 133 diagnosis codes identified as acute (i.e. sprain/strain, fracture) 
and 36 identified as chronic pain (i.e. fibromyalgia, rheumatoid arthritis) conditions; 
however, 90 patient encounters had no diagnosis codes associated with their encounter; 65 
had diagnoses which could be classified as either acute or chronic pain (i.e. back pain). Of 
the patients who could easily be classified as acute or chronic pain, about two-thirds had an 
acute pain diagnosis. The most common diagnoses were sprain/strain, contusion, fracture, 
and dental pain.
Over a quarter of opioid prescribing encounters (25.9%) resulted in a daily morphine 
milliequivalent dose of 50 or greater (Table 4), and 38.6% were written for more than 28 
days. Many of these patients had other risk factors for substance use disorder of controlled 
substances in addition to their history of overdose. Most notably, almost half (47.3%) of 
patients had a positive blood alcohol level or a positive toxicology screen for marijuana or 
cocaine at any time within their medical record. Additionally, 1 in 5 patients received an 
“early refill”, meaning that they had an active prescription documented in the EMR with 
more than half of the prescribed quantity (if taken as prescribed) remaining.
Hydrocodone and oxycodone containing compounds accounted for the majority (55.8%) of 
the medications prescribed during the subsequent encounter (Table 5). Benzodiazepines 
accounted for a quarter (25.5%) of the medications prescribed. Methadone, which is used for 
pain and may also be used for treatment of opioid use disorder, was prescribed to few 
patients (1.2%) in this cohort.
Discussion
High risk prescribing to patients with opioid overdose has previously been outlined in 
retrospective insurance claims data (Larochelle, Liebschutz et al. 2015, Naeger et al. 2016). 
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Our study examined detailed demographics and patient specific factors around prescribing to 
patients with a previous opioid or benzodiazepine overdose. The results demonstrate the 
occurrence of high risk prescribing of opioids or benzodiazepines in 404 unique patients 
over a one-month period in a large health care system. To the best of our knowledge, this is 
the first study to examine prescribing patterns in patients with prior overdose of 
benzodiazepines and/or opioids. It is of particular interest that opioids were involved in 
fewer than half of these overdoses, while benzodiazepines without opioids were implicated 
in 51% of overdoses. Benzodiazepines are known to rarely cause significant toxicity when 
ingested alone in an overdose (Hojer et al. 1989). However, the combination of 
benzodiazepines with opioids is known to be a risk factor for overdose death, and previous 
research suggests the longer a patient is on benzodiazepines, the higher the risk of a 
polysubstance overdose (Turner and Liang 2015, Bachhuber, Hennessy et al. 2016).
Having a previous overdose, whetherunintentional or by suicide attempt, presents a 
particularly high-risk scenario for subsequent opioid prescribing. While we found patients 
with previous overdose account for only 0.9% of all prescribing, the small percentage 
relative to the overall prescribing encounters for opioids and benzodiazepines should not 
diminish the significant risk for mortality specific to this population. This study represents 
patients in one large healthcare system over one month, but extrapolating these numbers to 
describe potential risk across the US over time leads to large numbers and accounts for 
significant morbidity and mortality. This risk is highlighted in previous research from the VA 
that shows 82% of patients with an opioid overdose were subsequently prescribed opioids 
and 25% of those patients went on to have another overdose (Boyle et al. 2017). Therefore, 
this high risk cohort should be identified through clinical decision support to mobilize 
clinicians to evaluate risk and mobilize harm reduction strategies. Risk mitigation strategies 
that can be employed include opioid alternative therapies to reduce daily MME in those who 
have opioid dependence and to avoid repeat opioid exposure in those who are not currently 
dependent on opioids. Additionally, naloxone co-prescribing can be implemented in this 
high risk group, particularly in patients that are co-prescribed benzodiazepines with opioids. 
Furthermore, many patients have other risk factors in addition to the previous overdose, with 
almost half having a history of a positive alcohol, cocaine, or marijuana toxicology screen in 
their medical record and this should be included in a clinical decision support tool.
Through chart abstraction, we outlined the suspected cause of overdose in the data, whether 
unintentional or from suicide attempt. The large number of patients with suicide attempt 
(40%) in this cohort highlights the complex behavioral health comorbidities that exist in this 
high-risk population. Mental health disorders, particularly depression and post-traumatic 
stress disorder, are commonly comorbid with substance use disorder and overdose (Bohnert 
et al. 2011, Turner and Liang 2015, Wilder et al. 2016). Not surprisingly, the risk of opioid 
dependence and misuse increases with comorbid mental health disorders in both acute and 
chronic pain (Edlund et al. 2007, Helmerhorst et al. 2014). Our study provides further 
evidence to the correlation of mental health disorders with substance use disorders. Our 
results suggest that mental health comorbidities and a history of a previous suicide attempt 
should motivate prescribers to consider alternatives to opioids for pain control.
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Most of the prescribing after an overdose occurred in the outpatient setting, whether from 
outpatient clinics or emergency departments. It is unclear if prescribers were aware of the 
previous overdose and we were unable to obtain this information from chart abstraction. We 
were surprised to discover that 27.4% of the prescribing encounters occurred during a 
medical phone call consultation. We suspect these visits are for patients that are calling their 
primary prescribers for treatment after previously establishing care with that provider, as 
there is no clinic visit note for these encounters. Our results suggest that providers should be 
particularly cautious when prescribing controlled substance following a telephonic medical 
encounter.
Additionally, risk factors of opioid dependence and opioid use disorder were identified in the 
database, including positive toxicology screens in 47.3% of patients. Tobacco, cannabis, and 
alcohol use disorders are known to be comorbid substance use disorders in patients at risk 
for overdose and increase the risk of repeat overdose in this population (Edlund, Sullivan et 
al. 2007, Fiellin et al. 2013). Prescribers should be screening for comorbid substance use 
disorders in patients they are considering for opioid therapy and prioritize non-opioid 
therapies in this population.
The high-risk prescribing identified in our study suggests providers may not be adequately 
identifying risk factors present in patients who are receiving benzodiazepines and/or opioids. 
At least one-third of these prescriptions were given opioids for chronic conditions, 
suggesting that prescribers decided to either initiate or continue opioids in conditions that 
have poor evidence for long term improvement in function or pain from opioid therapy and 
despite the previously documented risk factor of overdose in the chart. The large percentage 
of patients (25.9%) receiving greater than 50 MME of opioids a day is particularly 
concerning in this cohort, given the increased risk of overdose at this daily dose. Also, the 
5% of patients receiving a combination of opioids and benzodiazepines in this cohort is 
particularly concerning given a history of overdose and known increased risk of adverse 
outcomes with this combination of medications.
These results suggest prescribers may need better tools to help in identifying patients at risk 
for overdose and substance use disorders. The electronic tool used to identify the patients in 
this cohort is also being developed as a clinical decision support tool. The diagnoses listed at 
time of prescribing, such as sprains and strains, suggest many of these conditions could be 
treated with opioid sparing modalities and a next step in our ongoing investigation is to 
explore whether the knowledge of overdose via this EMR alert changes prescribing 
behavior. This data suggests more tools like this will be needed to identify patients at higher 
risk of opioid or benzodiazepine use disorders. Additionally, providers will need training in 
alternatives to opioids to managing pain. More investment in multimodal pain management 
will be required in this patient population.
Since this study was a retrospective chart review of prospectively identified patients, there 
were several limitations. First, due to the nature of this dataset, we were unable to determine 
the proportion of patients with a history of overdose who were prescribed a controlled 
substance. However, this question has already been addressed (Larochelle, Liebschutz et al. 
2015). This paper sought to describe these scenarios in a more detailed fashion. This paper 
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did not seek to determine the “appropriateness” of the prescriptions, but rather to assess the 
risk involved. We did examine the diagnosis codes at the time of prescribing to better 
characterize this encounter but found that many of the visits were missing diagnosis codes in 
our dataset, limiting the accuracy of this data point. The drugs indicated as the cause of the 
overdose were obtained by reviewing chart documentation. Therefore, the identified cause of 
overdose was abstracted from the clinical determination made during the hospital visit and 
did not always include a laboratory analysis of blood or urine. In general, urine drug screens 
are commonly used in overdose patients in the clinical setting, but commonly fail to identify 
the causative agent due to the inability of the test to detect many of the commonly used 
substances. Like in the clinical setting, this retrospective study must rely on the patients’ 
clinical presentation in addition to laboratory analysis, which may limit the accuracy in 
some cases. Similarly, the determination as to whether the patient made a suicide attempt or 
unintentionally overdosed was determined by data provided by clinician and consultants in 
the medical record. While it is good clinical care to inquire about the intent of an overdose, 
even among those who have a long history of opioid use disorder, it is unclear if providers 
accurately investigate the motive behind the overdose or if the patient accurately reported 
their motive, which may limit the accuracy of this data point. This study did not follow 
patients after receiving these prescriptions to detect further overdose. This should be 
explored in future studies to determine the risk involved in prescribing to this patient 
population. Finally, this analysis was limited to data within our healthcare system’s 
electronic medical record. Therefore, diagnoses, treatments, and prescriptions from 
encounters outside this system were not captured.
Conclusions
In conclusion, prescribing of opioids and benzodiazepines occurs across multiple locations 
in a large health care system to patients with a previous overdose. These patients have a high 
level of comorbidities, particularly mental health disorders and substance use disorders. Risk 
factors such as previous overdose should be highlighted through clinical decision support 
tools in the medical record to help prescribers identify patients at higher risk and to mobilize 
resources for this patient population. Prescribers need further education on factors that place 
their patients at risk for opioid and benzodiazepine use disorders and on alternative therapies 
to opioids and benzodiazepines, particularly in high risk patients
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Figure 1: 
Patient Selection Diagram.
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Table 1.
Overdose diagnosis codes used as inclusion criteria
ICD 9 ICD 10
96509 Poisoning by opiate/related narcotic T402X1A Poisoning by other opioids, accidental (unintentional), initial encounter
T402X2A Poisoning by other opioids, intentional self-harm, initial encounter
T402X3A Poisoning by other opioids, assault, initial encounter
T402X4A Poisoning by other opioids, undetermined, initial encounter
T404X1A Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter
T404X2A Poisoning by other synthetic narcotics, intentional self-harm, initial encounter
T404X3A Poisoning by other synthetic narcotics, assault, initial encounter
T404X4A Poisoning by other synthetic narcotics, undetermined, initial encounter
T40601A Poisoning by unspecified narcotics, accidental (unintentional), initial encounter
T40602A Poisoning by unspecified narcotics, intentional self-harm, initial encounter
T40603A Poisoning by unspecified narcotics, assault, initial encounter
T40604A Poisoning by unspecified narcotics, undetermined, initial encounter
T40691A Poisoning by other narcotics, accidental (unintentional), initial encounter
T40692A Poisoning by other narcotics, intentional self-harm, initial encounter
T40693A Poisoning by other narcotics, assault, initial encounter
T40694A Poisoning by other narcotics, undetermined, initial encounter
9694 Poisoning by benzodiazepine-based 
tranquilizer
T424X1A Poisoning by benzodiazepines, accidental (unintentional), initial encounter
T424X2A Poisoning by benzodiazepines, intentional self-harm, initial encounter
T424X3A Poisoning by benzodiazepines, assault, initial encounter
T424X4A Poisoning by benzodiazepines, undetermined, initial encounter
J Addict Med. Author manuscript; available in PMC 2020 September 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Griggs et al. Page 13
Table 2.
Characteristics of Patients with Previous Overdose Receiving Opiate/Benzodiazepine Prescriptions (n = 404)
Variable N %
Age
<18
18–34
35–49
50–64
65+
2
76
152
133
41
0.5
18.8
37.6
32.9
10.1
Average Age at Prescription 46.9 (13.4); Range: 16–87
Average Age at Overdose 44.8 (13.5) Range: 13.9–82.2
Cause of Overdose
Unintentional
Suicide Attempt
Unknown/Missing
206
163
35
51.0
40.3
8.7
Overdose Substance
Opiate only
Benzodiazepine only
Both
Missing
74
207
114
9
18.3
51.2
28.2
2.2
Comorbidities
Schizophrenia
Bipolar
Anxiety
Depression
Substance Use Disorder
17
97
220
223
118
4.2
24.0
54.5
55.2
29.2
Number of Prescribing Encounters
1
2
3
4
5
307
65
24
6
2
76.0
16.1
5.9
1.5
0.5
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Table 3.
Characteristics of Prescribing Encounters (n=527)
Drug Prescribed
Opioid
Benzodiazepine
Both
390
126
27
71.8
23.2
5.0
Years Since Overdose
0
1
2
3
4
5
6
7
55
137
102
97
59
49
35
9
10.1
25.2
18.8
17.9
10.9
9.0
6.5
1.7
Location of Prescribing Encounter
Behavioral Health
Cancer
ED
Follow-up/Phone
Inpatient Discharge
Other
Outpatient Procedures
Primary Care
Specialty Care
Urgent Care
Unknown
28
4
171
149
40
3
14
71
37
8
18
5.2
0.7
31.5
27.4
7.4
0.6
2.6
13.1
6.8
1.5
3.3
Also Had Other Risk Factors
3+ prescriptions
2+ onsite administrations
50% remaining (“early refill”)
Positive BAC or toxicology
 BAC
 Marijuana
 Cocaine
53
42
109
257
 129
 139
 88
9.8
7.7
20.0
47.3
 23.8
 25.6
 16.2
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Table 4.
MME details of opiate prescriptions given to patients with prior overdose (n=417)
Encounters
with Opioids
N %
MME Daily Dose
0–20
21–49
50–99
100+
Missing
134
163
76
32
12
32.1
39.1
18.2
7.7
2.9
MME Total
0–250
251–500
501–750
751–1000
>1000
Missing
174
70
28
18
115
12
41.7
16.8
6.7
4.3
27.6
2.9
Average MME Total 1037 (SD = 1695) range: 15 – 10800
Median MME Total 375 (IQR = 1088)
Average mme/day 47.0 (SD = 48.6) range: 5.0 – 360.0
Median MME/day 30.0 (IQR = 40)
Average duration 19.4 (SD = 22.9) range: 1 – 180 days
Duration
0–3 days
4–7 days
8–14 days
15–21 days
22–28 days
>28 days
Missing
88
72
57
17
10
161
12
21.1
17.3
13.7
4.1
2.4
38.6
2.9
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Table 5:
Medications prescribed at subsequent encounter, n = 647
Medication N %
Benzodiazepines
LORazepam 36 5.6
chlordiazePOXIDE 3 0.5
clonazePAM 67 10.4
diazepam 13 2.0
temazepam 7 1.1
ALPRAZolam 38 5.9
Opioids
HYDROcodone-acetaminophen 181 28.0
HYDROmorphone 8 1.2
acetaminophen-codeine 3 0.5
butalbital/ASA/caffeine/codeine 1 0.2
butorphanol 2 0.3
fentaNYL 15 2.3
methadone 8 1.2
morphine 6 0.9
oxyCODONE 80 12.4
oxyCODONE-acetaminophen 101 15.6
oxymorphone 7 1.1
tapentadol 1 0.2
traMADol 70 10.8
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